Search tool

In accordance with Article 92 of the Financial Regulation applicable to the EMCDDA, the accounts of the EMCDDA shall comprise: 'The financial statements of the EMCDDA and the reports on implementation of...

The series ‘A year in review’ contains the essence of the EMCDDA's General Report of Activities. It is designed to provide interested audiences with a brief, four-page summary of the agency’s achievements...

The report describes trends in drug injection in the EU Member States, Norway and Turkey between 2000 and 2011, through an analysis of data on those admitted to drug treatment. Results indicate...

At the request of the Ministry of Health in Riga, a team of experts from European Center for Disease Prevention and Control and the EMCDDA paid a technical visit to Latvia on...

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its...

Cannabis is Europe’s most commonly used illicit drug, with around 20 million adults (15–64 years) having used it in the last year; around 3 million on a daily, or almost daily, basis...

This brochure provides an overview of the 2015 European Drug Report package and includes brief summaries of the four new additions to the Perspectives on drugs (PODs) series.

Changing dynamics in the heroin market, the latest implications of cannabis use and new features and dimensions of the stimulant and ‘new drugs’ scene are among the issues highlighted in the European...

Over 80 synthetic cathinone derivatives were detected via the EU Early Warning System (EU–EWS) between 2005 and 2014. This analysis explores new worrying localised and national outbreaks of injecting these substances and...

In this issue: European Drug Report 2015 highlights | Growing importance of effective treatment for cannabis use | Lisbon Addictions 2015 | European drugs summer school 2015 | First overview of the...